HC Wainwright Raises Earnings Estimates for Rockwell Medical

Rockwell Medical, Inc. (NASDAQ:RMTI) – HC Wainwright boosted their Q3 2027 earnings per share (EPS) estimates for Rockwell Medical in a report released on Thursday, July 9th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.13 per share for the quarter, up from their previous forecast of $0.10. HC Wainwright currently has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Rockwell Medical’s Q4 2027 earnings at $0.15 EPS.

Rockwell Medical (NASDAQ:RMTI) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.30). The business had revenue of $17.34 million for the quarter, compared to analyst estimates of $17.95 million. Rockwell Medical had a negative return on equity of 15.41% and a negative net margin of 7.98%.

Other equities research analysts have also issued reports about the stock. Weiss Ratings lowered shares of Rockwell Medical from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 15th. Wall Street Zen upgraded Rockwell Medical from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Rockwell Medical has a consensus rating of “Hold” and an average target price of $20.00.

Rockwell Medical Stock Performance

Shares of RMTI opened at $5.76 on Friday. The firm has a market cap of $22.75 million, a P/E ratio of -3.84 and a beta of 1.61. Rockwell Medical has a twelve month low of $4.89 and a twelve month high of $21.00. The company has a debt-to-equity ratio of 0.23, a quick ratio of 3.43 and a current ratio of 3.74. The firm’s 50 day moving average price is $7.06 and its two-hundred day moving average price is $8.72.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Corsair Capital Management L.P. acquired a new stake in Rockwell Medical in the 1st quarter valued at about $45,000. Renaissance Technologies LLC increased its position in Rockwell Medical by 36.5% during the first quarter. Renaissance Technologies LLC now owns 639,120 shares of the company’s stock worth $571,000 after buying an additional 170,800 shares during the last quarter. Geode Capital Management LLC raised its stake in Rockwell Medical by 12.9% in the fourth quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock valued at $304,000 after buying an additional 41,668 shares during the period. Vanguard Group Inc. raised its stake in Rockwell Medical by 12.3% in the third quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock valued at $1,625,000 after buying an additional 148,737 shares during the period. Finally, Jane Street Group LLC acquired a new stake in shares of Rockwell Medical in the fourth quarter valued at approximately $84,000. 23.31% of the stock is currently owned by institutional investors and hedge funds.

Rockwell Medical Company Profile

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.